XML 50 R26.htm IDEA: XBRL DOCUMENT v2.4.0.6
OPERATING SEGMENT AND GEOGRAPHIC INFORMATION (Tables)
 9 Months Ended
Sep. 30, 2012
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
 
 
 
 
 
 
 
 
 
Dollars in Thousands
 
2011
 
Clinical Laboratories
 
Pharmacogenomic Services
 
Diagnostic
Tools
 
Total
Net Sales
$
4,085

 
$
552

 
$
3,616

 
$
8,253

Gross Profit
2,456

 
241

 
1,748

 
4,445

Net Income (Loss) before Taxes
(1,472
)
 
122

 
71

 
(1,279
)
Income Tax Expense (Benefit)
(20
)
 
—

 
11

 
(9
)
Net Income (Loss)
$
(1,452
)
 
$
122

 
$
60

 
$
(1,270
)
Depreciation/Amortization
$
350

 
$
75

 
$
56

 
$
481

Restructure
$
2

 
$
—

 
$
3

 
$
5

Interest Expense, net
$
(238
)
 
$
—

 
$
—

 
$
(238
)
 
 
 
 
 
 
 
 
 
September 30, 2011
Total Assets
$
20,822

 
$
953

 
$
8,199

 
$
29,974

 
 
 
 
 
 
 
 
 
Dollars in Thousands
 
2011
 
Clinical Laboratories
 
Pharmacogenomic Services
 
Diagnostic
Tools
 
Total
Net Sales
$
11,435

 
$
1,824

 
$
10,141

 
$
23,400

Gross Profit
6,787

 
764

 
5,601

 
13,152

Net Income (Loss) before Taxes
(11,331
)
 
615

 
551

 
(10,165
)
Income Tax Benefit
—

 
—

 
(120
)
 
(120
)
Net Income (Loss)
$
(11,331
)
 
$
615

 
$
671

 
$
(10,045
)
Depreciation/Amortization
$
1,113

 
$
184

 
$
209

 
$
1,506

Restructure
$
28

 
$
—

 
$
12

 
$
40

Interest Expense, net
$
(720
)
 
$
—

 
$
—

 
$
(720
)
 
 
 
 
 
 
 
 
Segment information for the nine months ended September 30, 2012 and 2011 is as follows:
 
Dollars in Thousands
 
2012
 
Clinical Laboratories
 
Pharmacogenomic Services
 
Diagnostic
Tools
 
Total
Net Sales
$
13,329

 
$
1,198

 
$
9,661

 
$
24,188

Gross Profit
6,693

 
418

 
4,355

 
11,466

Net Loss before Taxes
(4,309
)
 
(310
)
 
(1,307
)
 
(5,926
)
Income Tax Expense
—

 
—

 
88

 
88

Net Loss
$
(4,309
)
 
$
(310
)
 
$
(1,395
)
 
$
(6,014
)
Depreciation/Amortization
$
1,265

 
$
92

 
$
213

 
$
1,570

Restructure
$
—

 
$
—

 
$
—

 
$
—

Interest Expense, net
$
(665
)
 
$
(11
)
 
$
(37
)
 
$
(713
)
 
 
 
 
 
 
 
 
Segment information for the three months ended September 30, 2012 and 2011 is as follows:
 
 
Dollars in Thousands
 
2012
 
Clinical Laboratories
 
Pharmacogenomic Services
 
Diagnostic
Tools
 
Total
Net Sales
$
4,498

 
$
220

 
$
3,171

 
$
7,889

Gross Profit
2,385

 
(38
)
 
1,453

 
3,800

Net Loss before Taxes
(1,694
)
 
(213
)
 
(733
)
 
(2,640
)
Income Tax Expense
—

 
—

 
114

 
114

Net Loss
$
(1,694
)
 
$
(213
)
 
$
(847
)
 
$
(2,754
)
Depreciation/Amortization
$
418

 
$
24

 
$
53

 
$
495

Interest Expense, net
$
(201
)
 
$
—

 
$
(6
)
 
$
(207
)
 
 
 
 
 
 
 
 
 
September 30, 2012
Total Assets
$
28,822

 
$
1,731

 
$
12,334

 
$
42,887
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas
Net sales for the three and nine months ended September 30, 2012 and 2011 by country were as follows:
 
 
Dollars in Thousands
 
Dollars in Thousands
 
Three Months Ended
 
Nine Months Ended
 
September 30,
 
September 30,
 
2012
 
2011
 
2012
 
2011
United States
$
5,442

 
$
6,034

 
$
17,013

 
$
16,738

Italy
571

 
762

 
2,277

 
2,373

United Kingdom
546

 
193

 
1,113

 
451

France
264

 
166

 
575

 
579

Germany
517

 
187

 
769

 
581

All Other Countries
549

 
911

 
2,441

 
2,678

Total
$
7,889

 
$
8,253

 
$
24,188

 
$
23,400